Company Filing History:
1 out of 1,745 
1 out of 20 
1 out of 37 
Years Active: 2024
Title: The Innovative Contributions of Daniel Gonzalez in Cancer Treatment
Introduction
Daniel Gonzalez is a notable inventor based in Dijon, France. He has made significant strides in the field of cancer treatment through his innovative research and development of compounds targeting the HSP110 protein. His work focuses on creating effective therapies for HSP110-associated cancers, such as colorectal cancer and lymphoma.
Latest Patents
Gonzalez holds a patent for compounds that inhibit HSP110, which bind directly to the nucleotide binding domain of the protein. This binding action blocks the phosphorylation of STAT3, thereby inhibiting cancer cell growth and stabilizing MyD88. His patent describes a compound of formula (I) that is particularly effective in treating HSP110-associated cancers. In preclinical studies, an exemplary compound was tested on syngeneic models, where mouse colon cancer CT-26 cells were injected into Balb/c mice, as well as on a NOD/SCID model with human colorectal cancer HCT116 cells. The results showed that the compound induced tumor regression in these models, which was linked to the inhibition of various tumorigenic functions associated with HSP110, including resistance to apoptosis and the induction of pro-tumor macrophages. Furthermore, the compound demonstrated the ability to alter the interaction between HSP110 and MyD88, leading to the degradation of the oncogene MyD88. Notably, it has also been shown to act synergistically with other anti-cancer agents, including tyrosine kinase inhibitors like Ibrutinib.
Career Highlights
Throughout his career, Daniel Gonzalez has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Caen Normandie. His research has contributed to the understanding and treatment of various cancers, showcasing his commitment to advancing medical science.
Collaborations
Gonzalez has collaborated with notable colleagues, including Carmen Garrido Fleury and Gaetan Jego, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Daniel Gonzalez's innovative work in developing HSP110 inhibitors represents a significant advancement in cancer treatment. His contributions not only highlight his expertise but also pave the way for future research in oncology.